Pharmaceutical Technology: ESC 2024: Obesity Drugs Emerge as Attractive Tool for Heart Failure Prevention

Cardiology experts discussed the relationship between obesity and heart failure while referencing new clinical trial results at the European Society of Cardiology (ESC) 2024 Congress.

In one presentation, Dr. Mikhail Kosiborod, cardiologist and vice president of research at Saint Luke’s Mid America Heart Institute, emphasized the importance of understanding the systemic and local effects of obesity on heart failure and the need for further studies to comprehend the relationship between visceral adiposity and heart failure. Specifically, Kosiborod focused on different treatment strategies, such as lifestyle interventions, bariatric surgery and medications for the prevention of obesity to reduce the risk of heart failure and relevant clinical trial results.

Read the full Pharmaceutical Technology article: ESC 2024: Obesity Drugs Emerge as Attractive Tool for Heart Failure Prevention